Christoffer Polcwiartek1,2,3,4,5, Kristian Kragholm1,2,5,6, Steen M Hansen2, Brett D Atwater3, Daniel J Friedman3, Carlo A Barcella7, Claus Graff8, Jonas B Nielsen9, Adrian Pietersen10, Jimmi Nielsen11, Peter Søgaard1,4, Christian Torp-Pedersen1,2,4,8, Svend E Jensen1,4. 1. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. 2. Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark. 3. Division of Cardiology, Duke University Medical Center, Durham, NC. 4. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 5. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark. 6. Department of Cardiology, North Denmark Regional Hospital, Hjørring, Denmark. 7. Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark. 8. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark. 9. Laboratory for Molecular Cardiology, Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark. 10. Copenhagen General Practitioners' Laboratory, Copenhagen, Denmark. 11. Mental Health Center Glostrup, Copenhagen University Hospital Glostrup, Copenhagen, Denmark.
Abstract
BACKGROUND: There are limited data on electrocardiogram (ECG) characteristics and their association with psychotropic drugs in schizophrenia. METHODS: Using a cross-sectional design, we included Danish primary care patients with first-time digital ECGs from 2001 to 2015. Patients diagnosed with schizophrenia before ECG recording were matched 1:5 on age, sex, and ECG recording year to controls without psychiatric disease. Multivariable logistic regression was used to compute odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: We included 4486 patients with schizophrenia matched with 22 430 controls (median age, 47 years; male, 55%). Between groups, the prevalence of abnormal ECGs was similar (54%, P = .536), but patients with schizophrenia demonstrated higher median heart rate (79 vs 69 beats per minute, P < .001) and Fridericia-corrected QT (QTc) interval (416 vs 412 ms, P < .001) than controls. QTc prolongation was also more prevalent among patients with schizophrenia (3.4% vs 1.1%, P < .001), and so were pathological Q waves (5.3% vs 3.9%, P < .001). Patients with schizophrenia less frequently demonstrated left ventricular hypertrophy (6.1% vs 9.6%, P < .001) and atrial fibrillation or flutter (0.7% vs 1.4%, P < .001). Among patients with schizophrenia only, particularly antipsychotics were associated with abnormal ECGs (OR, 1.20; 95% CI, 1.04-1.39). CONCLUSIONS: Patients with schizophrenia demonstrate a different cardiovascular risk profile than matched controls without psychiatric disease, with higher prevalence of elevated heart rate, QTc prolongation, and pathological Q waves, and lower prevalence of left ventricular hypertrophy and atrial fibrillation or flutter. Particularly antipsychotics were associated with abnormal ECGs. This underscores an integrated care approach when ECG abnormalities are detected in this group.
BACKGROUND: There are limited data on electrocardiogram (ECG) characteristics and their association with psychotropic drugs in schizophrenia. METHODS: Using a cross-sectional design, we included Danish primary care patients with first-time digital ECGs from 2001 to 2015. Patients diagnosed with schizophrenia before ECG recording were matched 1:5 on age, sex, and ECG recording year to controls without psychiatric disease. Multivariable logistic regression was used to compute odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: We included 4486 patients with schizophrenia matched with 22 430 controls (median age, 47 years; male, 55%). Between groups, the prevalence of abnormal ECGs was similar (54%, P = .536), but patients with schizophrenia demonstrated higher median heart rate (79 vs 69 beats per minute, P < .001) and Fridericia-corrected QT (QTc) interval (416 vs 412 ms, P < .001) than controls. QTc prolongation was also more prevalent among patients with schizophrenia (3.4% vs 1.1%, P < .001), and so were pathological Q waves (5.3% vs 3.9%, P < .001). Patients with schizophrenia less frequently demonstrated left ventricular hypertrophy (6.1% vs 9.6%, P < .001) and atrial fibrillation or flutter (0.7% vs 1.4%, P < .001). Among patients with schizophrenia only, particularly antipsychotics were associated with abnormal ECGs (OR, 1.20; 95% CI, 1.04-1.39). CONCLUSIONS:Patients with schizophrenia demonstrate a different cardiovascular risk profile than matched controls without psychiatric disease, with higher prevalence of elevated heart rate, QTc prolongation, and pathological Q waves, and lower prevalence of left ventricular hypertrophy and atrial fibrillation or flutter. Particularly antipsychotics were associated with abnormal ECGs. This underscores an integrated care approach when ECG abnormalities are detected in this group.
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Jonas Bille Nielsen; Claus Graff; Adrian Pietersen; Bent Lind; Johannes Jan Struijk; Morten Salling Olesen; Stig Haunsø; Thomas Alexander Gerds; Jesper Hastrup Svendsen; Lars Køber; Anders Gaarsdal Holst Journal: J Am Coll Cardiol Date: 2013-04-12 Impact factor: 24.094
Authors: Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Jentien M Vermeulen; Geeske van Rooijen; Marita P J van de Kerkhof; Arjen L Sutterland; Christoph U Correll; Lieuwe de Haan Journal: Schizophr Bull Date: 2019-03-07 Impact factor: 9.306
Authors: Jonas Bjerring Olesen; Gregory Y H Lip; Morten Lock Hansen; Peter Riis Hansen; Janne Schurmann Tolstrup; Jesper Lindhardsen; Christian Selmer; Ole Ahlehoff; Anne-Marie Schjerning Olsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen Journal: BMJ Date: 2011-01-31
Authors: Christoffer Polcwiartek; Brett D Atwater; Kristian Kragholm; Daniel J Friedman; Carlo A Barcella; Rubina Attar; Claus Graff; Jonas B Nielsen; Adrian Pietersen; Peter Søgaard; Christian Torp-Pedersen; Svend E Jensen Journal: J Am Heart Assoc Date: 2021-01-12 Impact factor: 5.501